Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Leslie G. Lorello"'
Autor:
Leslie G. Lorello, Jim McNally, Hugh D. Conlon, Michael W. Leach, Carol F. Kirchhoff, Teresa Annette Smolarek, Andrew Saati, Sarah Koob, Mazin Derzi, Ahmed M. Shoieb, Penny Sharpe, Michael W. Bolt, Theodore R. Johnson
Publikováno v:
Advances in Therapy
Introduction PF-06438179, a potential biosimilar to Remicade® (infliximab, Janssen Biotech, Inc.), is a chimeric mouse–human monoclonal antibody targeting human tumor necrosis factor alpha (TNF). Methods Analytical (small subset reported here) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1eb4ef54c3121972985f519b27fd07
https://doi.org/10.1007/s12325-016-0403-9
https://doi.org/10.1007/s12325-016-0403-9
Autor:
Michael W. Leach, Leslie G. Lorello, Gregory L. Finch, Sharon L. Ripp, Ahmed M. Shoieb, Shawn P. O'Neil, Jameel Syed, Zaher A. Radi, Matthew S. Thompson, Mazin Derzi
Publikováno v:
Regulatory Toxicology and Pharmacology. 112:104587
Adalimumab, a recombinant fully human monoclonal antibody targeting tumor necrosis factor (TNF), is approved in the United States and Europe to treat various inflammatory and autoimmune indications. Biosimilars are approved biologics highly similar,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b782c4c13b3cd4d270d27d6799df466
https://doi.org/10.1016/j.yrtph.2020.104587
https://doi.org/10.1016/j.yrtph.2020.104587
Autor:
Mauricio Leal, Nicole Duriga, Judy Lucas, Franklin Spriggs, Eugene P. Kadar, Brian Rago, Jo-Ann Wentland, Quazi Shakey, Xiaogang Han, Wei Song, Jim McNally, Leslie G. Lorello, Yanhua Zhang, Puja Sapra
Publikováno v:
Bioconjugate chemistry. 26(11)
The pharmacokinetics of an antibody (huA1)-drug (auristatin microtubule disrupting MMAF) conjugate, targeting 5T4-expressing cells, were characterized during the discovery and development phases in female nu/nu mice and cynomolgus monkeys after a sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d25789a1784a3ef9e7205d6f1b0ec4a0
https://pubmed.ncbi.nlm.nih.gov/26180901
https://pubmed.ncbi.nlm.nih.gov/26180901
Autor:
Susan Hurst, Leslie G. Lorello, Michael W. Leach, Jim McNally, Teresa Annette Smolarek, Gregory L. Finch, Anne M. Ryan, Chee-Keng Ng, Josh A. Fohey, Stephen A. Ploch
Publikováno v:
Biodrugs
Background and Objectives Trastuzumab (Herceptin®) is a humanized monoclonal antibody (mAb) that binds to the HER2 protein. PF-05280014 is being developed as a potential biosimilar to trastuzumab products marketed in the United States (trastuzumab-U
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5ea318c037ac153c41b4d087843a130